Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
View/ Open
Date
2017-05Author
George, A
Kaye, S
Banerjee, S
Type
Journal Article
Metadata
Show full item recordAbstract
The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. Germ line BRCA mutation status is now established as a predictive biomarker of potential benefit from treatment with a PARP inhibitor; therefore, knowledge of the BRCA status of an individual patient with ovarian cancer is essential, in order to guide treatment decisions. BRCA testing was previously offered only to women with a family or personal history of breast and/or ovarian cancer; however, almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA testing. A strategy to enable more widespread implementation of BRCA testing in routine care is, therefore, necessary. In this Review, we summarize data from key clinical trials of PARP inhibitors and discuss how to integrate these agents into the current treatment landscape of ovarian cancer. The validity of germ line BRCA testing and other promising biomarkers of homologous-recombination deficiency will also be discussed.
Collections
Subject
Humans
Ovarian Neoplasms
Germ-Line Mutation
Genes, BRCA1
Genes, BRCA2
Models, Genetic
Female
Clinical Trials as Topic
Genetic Testing
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Medicine Drug Development Unit (Kaye)
Language
eng
License start date
2017-05
Citation
Nature reviews. Clinical oncology, 2017, 14 (5), pp. 284 - 296